LifeMD, Inc. (NASDAQ:LFMD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $9.1429.

A number of brokerages have weighed in on LFMD. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Monday, May 4th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research report on Tuesday, May 26th. Finally, UBS Group restated a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th.

Institutional Investors Weigh In On LifeMD

Large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after buying an additional 2,235 shares during the last quarter. Creative Planning acquired a new stake in shares of LifeMD in the 2nd quarter valued at $272,000. JPMorgan Chase & Co. raised its holdings in LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Legal & General Group Plc lifted its position in LifeMD by 187.4% during the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after purchasing an additional 6,614 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of LifeMD by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after purchasing an additional 4,281 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

LifeMD Trading Up 0.4%

NASDAQ LFMD opened at $4.89 on Friday. The company has a market cap of $236.48 million, a P/E ratio of 97.82 and a beta of 1.98. The company has a fifty day simple moving average of $4.24 and a 200 day simple moving average of $3.77. LifeMD has a 1 year low of $2.56 and a 1 year high of $15.84.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%. Equities research analysts forecast that LifeMD will post -0.37 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.